Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Elan Corporation, plc (ELN) -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (4394)	5/23/2003 9:00:14 PM
From: Harold Engstrom	Respond to of 10345

Bill will be back from his vacation soon, but in the meantime: 3. I like what we have seen so far from new CEO: focus, focus, focus. More focus would be nice, too. 4. I am not sure new board is necessary - these guys might have actually learned something that they can now apply to help the company. I have been accused of being overly loyal, however. 7. Accounting does appear as simple as possible given the baggage and rate of change. I would like product lines broken out by rev/exp so that we can see contributions from divested or soon to be divested items. Probably too much to ask. 8. Changes last year were pretty drastic and might be sufficient. 9. What about Frova, Myobloc, Zonegran, etc... There is plenty to market here. If King can sell the heck out of Skelaxin with Elan's salesforce, why couldn't Elan?... 10. IR is a joke. The guy in NY seems to know less than we do. Damn. 11. My hope (this is clearly not an insight BTW) is that we see some real revenue gains for retained products. Would like to see this paired with continued paring of expenses so that the company's structure is mated properly with its revenue (i.e., the company should be profitable.) 12. Drug launch: c'mon Antegren! (to be said like someone cheering the 7 horse at Belmont.) H

To: Icebrg who wrote (4394)	5/23/2003 11:33:47 PM
From: William Partmann	Read Replies (1) \| Respond to of 10345

Calling KM a failure is an erroneous statement. These were predictions and what I thought best to make Elan a functioning company. My prediction was wrong because it was based on the assumption that Elan wanted to continue as a drug company. I subsequently stated, and still believe, Martin is here to stabilize the company and sell it. He is doing a great job at that. While I haven't done a complete assessment, the largest rises (two of them) were the apparent resolution(s) of the poison put issue. Martin hiring started a small one. The next bump of merit should be the SEC, but IMO that doesn't get you to 10. I don't think my list was too off. Bill